Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience

Şirin, Sait; Oysul, Kaan; Surenkok, Serdar; Sager, Omer; Dincoglan, Ferrat; Dırıcan, Bahar; Beyzadeoğlu, Murat

doi:10.2298/vsp1111961s

Cited by 48 publications

(25 citation statements)

References 35 publications

(76 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It seems that patients having GKRS-treated foci surrounded by brain parenchyma were more likely to suffer from posttreatment complications. Further, our target volume was smaller than that in previously published studies [1,29,30,31,32]. Contrast-enhancing areas are dense agglomerations of tumor cells with pathological blood supply.…”

Section: Discussionmentioning

confidence: 77%

“…Since the overall survival observed in our group - 25.6 months - was exceptionally long compared to that of other published studies, it might lead to the conclusion that the presented group was extremely selected and not representative of GBM patients [1,10,26,30,32,33,34]. Pyrosequencing became available in our center in autumn 2013; thus, MGMT promoter methylation results were not known at the time of treatment decision.…”

Section: Discussionmentioning

confidence: 84%

See 1 more Smart Citation

Gamma Knife Radiosurgery in Recurrent Glioblastoma

Frischer

Marosi

Wöehrer³

et al. 2016

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

Background: We evaluated Gamma Knife radiosurgery (GKRS) as a treatment option for patients with recurrent glioblastoma. Patients and Methods: 42 patients with histopathologically diagnosed recurrent grade IV tumor were treated with GKRS. All patients had undergone standard multimodal first-line treatment. The average time from diagnosis to GKRS was 17.0 months. The median target volume was 5.1 cm³. The median margin dose was 10 Gy and the median central dose 20 Gy. In a subset of patients, O⁶-methylguanine methyltransferase (MGMT) promoter methylation analysis by pyrosequencing was performed. Results: Most patients did not develop complications after GKRS. Time to radiological progression after initial GKRS was 4.4 months (95% CI: 3.1-5.7 months). Radiological progression mainly occurred beyond the GKRS-irradiated area. The median survival time after initial GKRS was 9.6 months (95% CI: 7.7-11.5 months). The median overall survival time from diagnosis was 25.6 months (95% CI: 21.8-29.3 months). Patients with MGMT promoter methylation survived significantly longer (33.4 months; 95% CI: 21.2-45.5 months) compared to patients without MGMT promoter methylation (16.0 months; 95% CI: 8.0-23.9 months). Conclusion: GKRS seems to be a relatively safe salvage treatment option for recurrent glioblastoma for highly selected patients but must be seen as part of a multimodal treatment algorithm.

show abstract

Section: Discussionmentioning

confidence: 77%

Section: Discussionmentioning

confidence: 84%

Gamma Knife Radiosurgery in Recurrent Glioblastoma

Frischer

Marosi

Wöehrer³

et al. 2016

Stereotact Funct Neurosurg

View full text Add to dashboard Cite

show abstract

“…Sirin et al (14) had an improved median OS of 21 months as compared with the previously mentioned two investigators (3,5), while using the regimen of FEBRT and TMX in 58% followed by LINAC SRS. The GBM patients of Sirin et al underwent more STRs and fewer GTRs than those of Elliott et al (5), however, Sirin et al used a 3-mm margin around the contrast-enhancing margin on T1-weighted magnetic resonance imaging (MRI) at the time of SRS treatment.…”

mentioning

confidence: 85%

“…The GBM patients of Sirin et al underwent more STRs and fewer GTRs than those of Elliott et al (5), however, Sirin et al used a 3-mm margin around the contrast-enhancing margin on T1-weighted magnetic resonance imaging (MRI) at the time of SRS treatment. This was "to cover potential microscopic expansion of the recurrent tumor" (14). Also, in support of the use of this extended margin, Park et al stated that "tumors tend to progress within 2 cm of the contrast-enhancing edge"(11).…”

mentioning

confidence: 99%

Outcomes After Stereotactic Radiosurgery and Various Adjuvant Treatments for Recurrent Glioblastoma Multiforme: A Current Literature Review and Comparison of Multiple Factors that Impact Outcome

Murovic

Chang

2012

World Neurosurgery

View full text Add to dashboard Cite

“…However, disease recurrence is exceedingly common despite multimodal management. Repeat surgery, systemic agents and RT may be used in the recurrent setting as salvage therapeutic options, nevertheless, the clinical course is typically progressive with almost all patients ultimately succumbing to their disease [3][4][5] .…”

Section: Introductionmentioning

confidence: 99%

A concise review of immunotherapy for glioblastoma

Sager¹,

Dincoglan²,

Demiral³

et al. 2018

Self Cite

View full text Add to dashboard Cite

Glioblastoma (GB) is the most common and aggressive form of primary brain tumors in adults with a universally poor prognosis despite multimodal management including surgery, chemotherapy and radiation therapy. Among the novel therapeutic strategies, immunotherapy deserves particular attention with its potential to evoke biologic response and harness the host immune system. Considerable success achieved for other tumors has elicited great enthusiasm and prompted research on immunotherapy for GB. While the central nervous system has traditionally been thought of as an immune-privileged site, our understanding is being refined with emerging evidence. Several studies have been conducted and more are under way to establish the role of immunotherapy in management of GB. Immunotherapy of GB has yet resulted in mixed success with conflicting research findings, emphasizing the need for extensive study before its integration into routine clinical practice. Although there is a lot of room for improvement, immunotherapy for GB may be feasible and serve as a viable management strategy broadening and strengthening the therapeutic armamentarium to combat this deadly disease. Herein, we present a concise review of immunotherapy for GB.

show abstract

Linear accelerator-based stereotactic radiosurgery in recurrent glioblastoma: A single center experience

Abstract: Single-dose LINAC-based SRS is a safe and well- tolerated palliative therapeutic option in the management of patients with recurrent GB.

Cited by 48 publications

References 35 publications

Gamma Knife Radiosurgery in Recurrent Glioblastoma

Gamma Knife Radiosurgery in Recurrent Glioblastoma

Outcomes After Stereotactic Radiosurgery and Various Adjuvant Treatments for Recurrent Glioblastoma Multiforme: A Current Literature Review and Comparison of Multiple Factors that Impact Outcome

A concise review of immunotherapy for glioblastoma

Contact Info

Product

Resources

About